Clinical study

Researchers are investigating fungal contributions to IBD-related gut inflammation; understanding fungal persistence mechanisms could eventually inform therapies or diagnostics for dysbiosis-associated worsening of...

Researchers found that nearly all people with UC have high-titer autoantibodies to the epithelial integrin αvβ6 that can precede disease and associate with worse outcomes. Understanding whether and how these antibodies...

This project explores a specific molecular pathway (WNT2B → NF-κB/IL‑6) that may protect the colon from inflammation. If validated, it could identify a new therapeutic target for IBD and help explain why some people...

The study targets REV-ERBα, a regulator of TH17 cells that contribute to Crohn’s disease and ulcerative colitis, so its findings could identify new molecular pathways to target for IBD therapies.

Researchers are exploring whether vagus nerve stimulation or drugs targeting the α7 nicotinic receptor could reduce liver inflammation from heavy alcohol use. If mechanisms are confirmed, this could point to new...

This project aims to map microbe-specific T cells in Crohn's disease using single-cell RNA and TCR sequencing. Findings could reveal antigen-specific mechanisms driving IBD and help lay groundwork for targeted...

The project targets patients with refractory IBD who lack effective options; a new allogeneic stromal cell therapy could expand treatment choices for people who fail multiple drugs. The work focuses on immune pathways...

Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...

Pregnant people with IBD or other autoimmune diseases often face tough choices about continuing biologics or JAK inhibitors. CARE-HP aims to produce broader, disease-specific evidence to help patients and clinicians...

If intestinal stem cells retain an inflammatory “memory,” that could help explain why some people with IBD have persistent barrier problems and repeated flares despite therapy. Discovering durable molecular changes in...

This project aims to develop a new anti-inflammatory therapy targeting TREM-1 on macrophages, a pathway implicated in IBD. If successful, the approach could offer an alternative for patients who do not respond to current...

A quantitative, biopsy-based measure of collagen architecture could help study intestinal fibrosis, which underlies stricture formation in Crohn’s disease. Feasibility data support further validation work that may lead...

Oral and upper-GI involvement in Crohn's can be missed and may change how disease is diagnosed and managed. A focused review helps clinicians and researchers spot gaps in diagnostics and treatment research.

Patients with IBD often have joint and skin comorbidities that drive symptoms and treatment choices.

Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...

Genetic evidence for causal links between other diseases (for example asthma or multiple sclerosis) and IBD can help researchers prioritize biological pathways and potential therapeutic targets, and may explain why some...

This study provides real‑world data on how long biologic‑experienced UC patients stay on ustekinumab, which helps patients and clinicians set expectations about drug persistence and factors that might influence stopping...

Fibrosis and stricture formation are important complications in Crohn’s disease; a biopsy-based, quantitative way to measure collagen architecture could help research into fibrotic disease mechanisms and eventually...

Pathological features of intestinal lesions help doctors and researchers understand disease progression, identify complications, and interpret biopsies. Improvements or corrections to such descriptions can affect how...

This preclinical study suggests a heat‑killed form of Lactobacillus acidophilus LA‑5 reduced inflammation, oxidative stress, and markers of regulated cell death in a mouse model of ulcerative colitis — with effects...

For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...

Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.

Diet is a modifiable factor that could influence IBD risk through effects on the gut microbiome and immune pathways.

This registry study shows many people with IBD in Kazakhstan had clinically active disease at enrollment and identifies factors linked with active UC and CD. It highlights potential gaps in disease control and...

Both EEN and the Crohn’s disease exclusion diet are used to induce remission in children with Crohn’s disease. Evidence that they perform similarly through 52 weeks may help families and clinicians choose the approach...

This study builds a large, public single-cell map of the gut in Crohn’s disease that identifies cell types and gene programs linked to inflammation. That can help researchers find new drug targets and explain why some...

IBD patients sometimes use dietary strategies and supplements like curcumin for inflammation. This study describes a food-processing method that preserves curcumin activity and targets release to the intestine in lab...

People with IBD may experience cognitive symptoms; this preclinical study identifies specific quercetin glycosides that protected mice from colitis-related cognitive decline via gut microbiota and tryptophan metabolism...

This real-world multicenter study provides short-term effectiveness and safety data for upadacitinib in a difficult-to-treat Crohn’s population in China, which may inform treatment decisions and risk discussions.

These methods could help researchers and clinicians better identify which treatments are likely to work for which patients by combining trials and EHR data, accounting for multiple outcomes and missing data — relevant to...

If you have Crohn’s disease, upper GI biopsies showing focally enhanced gastritis or focally active inflammation could support a diagnosis of upper GI involvement and are associated with other histologic findings like...

People with IBD already have a higher baseline risk of colorectal cancer. This study finds that having multiple first‑degree relatives with CRC adds the largest absolute additional risk, which could affect how...

The study identifies Piezo1 in intestinal epithelial cells as a potential driver of intestinal fibrosis in IBD via a stiffness → ROS → partial EMT pathway, and suggests targeting Piezo1 or ROS could reduce fibrosis in...

If confirmed, molecular or microbial markers found at surgery could help identify Crohn’s patients at higher risk of postoperative endoscopic recurrence and inform closer monitoring or preventative strategies after...

The findings suggest that early biologic and immunomodulator treatment may reduce the need for first surgery in Crohn's disease, which is directly relevant to treatment planning and expectations for people with IBD.

If you or a child had Kawasaki disease, this study suggests there may be a higher long-term chance of certain skin autoimmune conditions (psoriasis, vitiligo) but no clear increase in IBD or several other autoimmune...

Malnutrition was common and much more frequent during active Crohn’s disease in this South Asian cohort, which matters because poor nutritional status affects treatment tolerance, recovery, and quality of life.

Mental health conditions (depression, anxiety, ADHD) appear to increase before and after IBD diagnosis, suggesting psychological care may be needed earlier in the diagnostic pathway and long term.

A blood test (serum REG3α) may help identify people at higher risk of developing complicated Crohn's disease years before diagnosis and predict progression in established disease, which could inform monitoring or early...

Finding reliable blood biomarkers for ulcerative colitis activity could make monitoring disease flares easier and less dependent on invasive tests. NGAL and S100A12 rising with active disease suggests they might help...

Sarcopenia (loss of muscle mass/strength) was common among hospitalized adults with active UC and linked to inflammation, changes in blood metabolites (bile acids, acylcarnitines), and shifts in the gut microbiome.

The work highlights macrophage metabolic programs and specific genes that may help classify UC molecular subtypes and suggest candidate biomarkers or therapeutic targets related to macrophage-driven inflammation.

If AJs and E-cadherin signaling influence intestinal inflammation, that could change how researchers think about IBD causes and point to new molecular targets for study.

PSC — a serious bile-duct disease linked to IBD — was found on MRCP in about 1 in 10 people at IBD diagnosis, often without abnormal liver blood tests. Early radiological detection could affect monitoring and specialist...

The study suggests that anti‑TNF treatment in IBD is associated with weaker and less cross‑reactive antibody and memory B‑cell responses after COVID‑19 booster vaccination, which may reduce durability of protection and...

Vitamin D deficiency is common in people with IBD and this study suggests correcting deficiency may help rebalance immune cells and the microbiome—potentially supporting inflammation control alongside standard...

People with Crohn’s who have had ileal or ileocolic surgery often worry about needing another operation; this study seeks clinical and biomarker predictors to estimate that risk. Understanding predictors could help...

If you or your clinician are using upadacitinib for Crohn’s, intestinal ultrasound early in treatment may help predict who will not respond and who is more likely to relapse on maintenance dosing, potentially guiding...